Henry Wong
Credentials | MD,PhD |
---|
Title | Professor |
---|
Institution | University of Arkansas for Medical Sciences |
---|
Department | Dermatology, College of Medicine |
---|
Address | 324 UAMS Campus Dr. Mail Slot # 576 Little Rock AR 72205
|
---|
Phone | 501-686-5111 |
---|
vCard | Download vCard |
---|
|
|
|
Overview Henry K. Wong, M.D., Ph.D. is Professor and Chairman of the University of Arkansas for Medical Sciences Department of Dermatology. Dr. Wong comes to UAMS from Ohio State University Medical Center in Columbus, Ohio, where he was director of immunodermatology and co-director of a multi-disciplinary cutaneous lymphoma clinic at the James Cancer Hospital and Comprehensive Cancer Center. He was also director of the psoriasis clinic, dermatology clinical trials, and the medical dermatology research fellowship at Ohio State. He is nationally known for his expertise on cutaneous T-cell lymphoma.Dr. Wong received his medical and doctoral degrees in biochemistry at New York University School of Medicine and the Sackler Institute of Graduate Biomedical Sciences in New York, NY. He was an intern at Barnes Hospital and the Washington University School of Medicine in St. Louis. Dr. Wong completed his residency in dermatology at Bellevue Hospital and New York University and was a visiting research fellow in immunology at the Cornell University School of Medicine.Wong has been chair of the Biomarker Committee of the U.S. Cutaneous Lymphoma Consortium since 2010, and became a member of the Clinical Guideline Committee of the American Academy of Dermatology in 2014. Since 2009, Dr. Wong has been recognized as one of the Best Doctors in Dermatology.Dr. Wong previously held faculty, research, and clinical positions at the Walter Reed Army Medical Center in Washington, D.C., as well as the Wayne State University School of Medicine and the Henry Ford Health System in Detroit.
Biography Director, Cutaneous Lymphoma Clinic
Dermatology Research
Research I01CX001895 (WONG, HENRY KEUNG)Apr 1, 2020 - Mar 31, 2024 NIH Epigenetic Regulation of Differentially Expressed Genes in Cutaneous T Cell Lymphoma Role: Principal Investigator |
| RD.06.SPR.118161 (WONG, HENRY)Mar 25, 2020 Galderma - Pass Through: Syneos Health A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderateto-Severe Atopic Dermatitis (249958) Role: Principal Investigator |
| M16-046 (WONG, HENRY)Jan 31, 2020 AbbVie Inc A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis (IRB 239608) Role: Principal Investigator |
| KPL (WONG, HENRY)Nov 22, 2019 - Jan 15, 2020 Kiniksa Pharmaceuticals, Ltd. KPL-716-C202: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Pilot Study to Investigate the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Diseases Characterized by Chronic Pruritus (IRB 249909) Role: Principal Investigator |
| KPL-716-C202 (WONG, HENRY)Nov 22, 2019 - Jan 15, 2020 Kiniksa Pharmaceuticals, Ltd. KPL-716-C202: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Pilot Study to Investigate the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Diseases Characterized by Chronic Pruritus (IRB 249909) Role: Principal Investigator |
| KPL-716-C201 (WONG, HENRY)Nov 22, 2019 Kiniksa Pharmaceuticals, Ltd. - Pass Through: Innovaderm Research, Inc. KPL-716-C201: A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects with Prurigo Nodularis (IRB 239539) Role: Principal Investigator |
| R3500-AD (WONG, HENRY)Sep 26, 2019 Regeneron Pharmaceuticals - Pass Through: PAREXEL International LLC A Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study to Assess the Efficacy and Safety of REGN3500 Monotherapy, and Combination of REGN3500 Plus Dupilumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis (229183) Role: Principal Investigator |
| R3500-AD-1798 (WONG, HENRY)Sep 26, 2019 Regeneron Pharmaceuticals - Pass Through: PAREXEL International LLC A Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study to Assess the Efficacy and Safety of REGN3500 Monotherapy, and Combination of REGN3500 Plus Dupilumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis (229183) Role: Principal Investigator |
| R3500-AD-1805 (WONG, HENRY)Sep 20, 2019 Regeneron Pharmaceuticals - Pass Through: PAREXEL International LLC R3500-AD-1805 A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 229151 Role: Principal Investigator |
| M16 (VEERAPUTHIRAN, MUTHU)Jul 26, 2019 AbbVie Inc Phase 1b Study of Venetoclax and Dinaciclib (MK7965) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (IRB 228481) Role: Principal Investigator |
| E7777-G000 (WONG, HENRY)Dec 27, 2018 Eisai A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma (IRB 228431) Role: Principal Investigator |
| E7777-G000-302 (WONG, HENRY)Dec 27, 2018 Eisai A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma (IRB 228431) Role: Principal Investigator |
| HPN-CTCL (WONG, HENRY)Oct 24, 2017 - Oct 25, 2020 Soligenix, Inc. SGX301- A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma Role: Principal Investigator |
| HPN-CTCL-01 (WONG, HENRY)Oct 24, 2017 - Oct 25, 2020 Soligenix, Inc. SGX301- A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma Role: Principal Investigator |
| EL (WONG, HENRY)Jul 11, 2017 - Jun 22, 2020 Elorac, Inc. Evaluate the safety and efficacy of topical naloxone hydrochloride lotion, 0.5%, for the relief of pruritus in patients with the mycosis fungoides (MF) form of cutaneous t-cell lymphoma (CTCL) Role: Principal Investigator |
| EL-1007-01-01 (WONG, HENRY)Jul 11, 2017 - Jun 22, 2020 Elorac, Inc. Evaluate the safety and efficacy of topical naloxone hydrochloride lotion, 0.5%, for the relief of pruritus in patients with the mycosis fungoides (MF) form of cutaneous t-cell lymphoma (CTCL) Role: Principal Investigator |
| CAIN457FUS01 (WONG, HENRY)Feb 6, 2017 - Feb 28, 2019 NOVARTIS Pharmaceuticals Corporation CHOICE STUDY Role: Principal Investigator |
| AIN457A2326 (WONG, HENRY K)Jan 17, 2017 - Jul 31, 2019 NOVARTIS Pharmaceuticals Corporation CLARITY Role: Principal Investigator |
| R21CA164911 (WONG, HENRY KEUNG)Jul 25, 2012 - Dec 30, 2014 NIH Novel Biomarkers in Cutaneous T Cell Lymphoma Role: Principal Investigator |
| R21AR052877 (WONG, HENRY KEUNG)Jul 17, 2006 - Jun 30, 2009 NIH Gene expression abnormalities in mycosis fungoides Role: Principal Investigator |
| K08AR047818 (WONG, HENRY KEUNG)Sep 20, 2002 - Jun 30, 2008 NIH Gene expression in memory CD4+T cells. Role: Principal Investigator |
Identifiers
|
Same Department
People who are also in this person's primary department.
|